PDCD1 and neoplasm: On another note, a phase 2 study is evaluating the combination of anti-PD-1 antibody (pembrolizumab) with re-irradiation and intra-tumoral administration of nanoparticles designed to destroy tumor cells when activated by RT for the treatment of inoperable locoregional recurrent head and neck squamous cell cancer (NCT04834349).